Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Chief Scientific Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 986,117 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 1,673 · Balance 986,117 F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2019 Filed Aug 5, 2019 13:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044382 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · CSO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,782,659 F1 · shares: Reflects an award of restricted stock units relating to 15,000 shares of the Issuer's common stock. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2019, and 1/16th of the remaining shares vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Gao's continued service for Issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantIssuer Common Stock | 1,767,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-144650 · doc4.xml · nonDerivative · entry 3 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,767,659 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1. F3 · price: The securities were received in the Reorganization in exchange for the cancellation of 13,434,211 Class D voting common units of the Predecessor. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Disposition to issuerPredecessor Class D Voting Common Units | 13,434,211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-144650 · doc4.xml · nonDerivative · entry 2 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1. F2 · price: The securities were disposed of and cancelled in the Reorganization in exchange for 1,767,659 shares of the Issuer's common stock. Read SEC document |
| May 13, 2016 Filed Oct 4, 2016 22:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SalePredecessor Class D Voting Common Units | 2,565,789 | $1.17 | $2,994,019.18 |
DisclosureSEC source: 0001209191-16-144650 · doc4.xml · nonDerivative · entry 1 Gao Hanlin · CIK 0001684532 · Chief Scientific Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,434,211 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.